Incyte Corporation (INCY)
Market Cap | 13.27B |
Revenue (ttm) | 3.77B |
Net Income (ttm) | 745.44M |
Shares Out | 224.86M |
EPS (ttm) | 3.30 |
PE Ratio | 17.88 |
Forward PE | 12.49 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,112,659 |
Open | 59.20 |
Previous Close | 60.87 |
Day's Range | 58.63 - 60.48 |
52-Week Range | 50.27 - 67.36 |
Beta | 0.74 |
Analysts | Buy |
Price Target | 71.14 (+20.54%) |
Earnings Date | Jul 30, 2024 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast ... [Read more]
Financial Performance
In 2023, Incyte's revenue was $3.70 billion, an increase of 8.87% compared to the previous year's $3.39 billion. Earnings were $597.60 million, an increase of 75.42%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $71.14, which is an increase of 20.54% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/e/7/software42-2507245.jpg)
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
![](https://cdn.snapi.dev/images/v1/u/v/press2-2477534.jpg)
Incyte Announces Final Results of Tender Offer
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Final Results of Tender Offer.
![](https://cdn.snapi.dev/images/v1/s/6/press10-2473107.jpg)
Incyte Announces Preliminary Results of Tender Offer
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Preliminary Results of Tender Offer.
![](https://cdn.snapi.dev/images/v1/z/q/press17-2469270.jpg)
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
![](https://cdn.snapi.dev/images/v1/a/b/press9-2468247.jpg)
Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific Interventions
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
![](https://cdn.snapi.dev/images/v1/a/h/press16-2454921.jpg)
Incyte Completes Acquisition of Escient Pharmaceuticals
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Escient Pharmaceuticals.
![](https://cdn.snapi.dev/images/v1/w/y/press14-2442140.jpg)
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings.
![](https://cdn.snapi.dev/images/v1/u/g/conf8-2441348.jpg)
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) i...
![](https://cdn.snapi.dev/images/v1/d/a/how-does-incyte-stocks-decline-2432077.jpg)
How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?
The stock price of Incyte Incyte , a biopharmaceutical company, trades at $58 per share, about 43% below its peak level of $100 seen in January 2021. INCY stock was trading at around $76 in early June...
![](https://cdn.snapi.dev/images/v1/w/1/press6-2430898.jpg)
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO24--Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress.
![](https://cdn.snapi.dev/images/v1/7/i/gettyimages-1493093301-4af383e-2428302.jpg)
S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan
Major U.S. equities indexes were mixed and little changed Monday to kick off a new trading week that will provide investors with a few key economic data points.
![](https://cdn.snapi.dev/images/v1/7/n/im-217725size1777777777777778w-2426665.jpg)
Incyte to buy back $1.67 billion of its own stock in Dutch auction tender
Biotech Incyte Corp. said Monday its board has approved a share buyback of up to $2 billion and the company has commenced a modified Dutch auction tender for up to $1.67 billion worth.
![](https://cdn.snapi.dev/images/v1/d/z/press9-2426551.jpg)
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock.
![](https://cdn.snapi.dev/images/v1/g/t/biotech36-2400177.jpg)
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.
![](https://cdn.snapi.dev/images/v1/q/f/press17-2399289.jpg)
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
![](https://cdn.snapi.dev/images/v1/j/c/press4-2384950.jpg)
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
![](https://cdn.snapi.dev/images/v1/r/m/conf17-2367021.jpg)
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 202...
![](https://cdn.snapi.dev/images/v1/j/t/press7-2350741.jpg)
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
WILMINGTON, Del. and HONG KONG--(BUSINESS WIRE)---- $INCY--Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia.
![](https://cdn.snapi.dev/images/v1/q/k/press2-2349650.jpg)
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that ...
![](https://cdn.snapi.dev/images/v1/p/m/press17-2348511.jpg)
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
![](https://cdn.snapi.dev/images/v1/g/f/press5-2316992.jpg)
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis.
![](https://cdn.snapi.dev/images/v1/t/z/press6-2316993.jpg)
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa.
![](https://cdn.snapi.dev/images/v1/7/a/press16-2306256.jpg)
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
![](https://cdn.snapi.dev/images/v1/q/e/press5-2301436.jpg)
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative ne...